Evidence map›Paper›PMID 35366874›Full record

ReviewCancer cell international2022

A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities.

Hossein Moutabian, Mehrsa Majdaeen, Ruhollah Ghahramani-Asl, Masoumeh Yadollahi, Esmaeil Gharepapagh, Gholamreza Ataei, Zahra Falahatpour, Hamed Bagheri, Bagher Farhood

Open access · goldAbstract readReview
In one paragraph

Review in Cancer cell international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Tuna trimmingsCurrent research in food science · 2023
    Article
  19. Review
  20. International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 1 country.

Hossein MoutabianRadiation Sciences Research Center (RSRC), AJA University of Medical Sciences, Tehran, Iran.
Mehrsa MajdaeenDepartment of Radiotherapy and Oncology, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Ruhollah Ghahramani-AslDepartment of Medical Physics and Radiological Sciences, Faculty of Paramedicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Masoumeh YadollahiDepartment of Allied Medical Sciences, Semnan University of Medical Sciences, Semnan, Iran.
Esmaeil GharepapaghMedical Radiation Sciences Research Team, Tabriz University of Medical Science, Tabriz, Iran.
Gholamreza AtaeiDepartment of Radiology Technology, Faculty of Paramedical Sciences, Babol University of Medical Sciences, Babol, Iran.
Zahra FalahatpourDepartment of Medical Physics, Tehran University of Medical Sciences, Tehran, Iran.
Hamed BagheriRadiation Sciences Research Center (RSRC), AJA University of Medical Sciences, Tehran, Iran. hamed_parto@yahoo.com.
Bagher FarhoodTrauma Research Center, Kashan University of Medical Sciences, Kashan, Iran. farhood-b@kaums.ac.ir.ORCID http://orcid.org/0000-0003-2290-7220
Aja University of Medical Sciences · IRBabol University of Medical Sciences · IRGuilan University of Medical Sciences · IRIran University of Medical Sciences · IRKashan University of Medical Sciences · IRSabzevar University of Medical Sciences · IRSemnan University of Medical Sciences · IRTabriz University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose5-fluorouracil (5-FU), an effective chemotherapy drug, is commonly applied for colorectal cancer treatment. Nevertheless, its toxicity to normal tissues and the development of tumor resistance are the main obstacles to successful cancer chemotherapy and hence, its clinical application is limited. The use of resveratrol can increase 5-FU-induced cytotoxicity and mitigate the unwanted adverse effects. This study aimed to review the potential therapeutic effects of resveratrol in combination with 5-FU against colorectal cancer.

methodsAccording to the PRISMA guideline, a comprehensive systematic search was carried out for the identification of relevant literature in four electronic databases of PubMed, Web of Science, Embase, and Scopus up to May 2021 using a pre-defined set of keywords in their titles and abstracts. We screened 282 studies in accordance with our inclusion and exclusion criteria. Thirteen articles were finally included in this systematic review.

resultsThe in vitro findings showed that proliferation inhibition of colorectal cancer cells in the groups treated by 5-FU was remarkably higher than the untreated groups and the co-administration of resveratrol remarkably increased cytotoxicity induced by 5-FU. The in vivo results demonstrated a decrease in tumor growth of mice treated by 5-FU than the untreated group and a dramatic decrease was observed following combined treatment of resveratrol and 5-FU. It was also found that 5-FU alone and combined with resveratrol could regulate the cell cycle profile of colorectal cancer cells. Moreover, this chemotherapeutic agent induced the biochemical and histopathological changes in the cancerous cells/tissues and these alterations were synergized by resveratrol co-administration (for most of the cases), except for the inflammatory mediators.

conclusionThe results obtained from this systematic review demonstrated that co-administration of resveratrol could sensitize the colorectal cancer cells to 5-FU treatment via various mechanisms, including regulation of cell cycle distribution, oxidant, apoptosis, anti-inflammatory effects.

Indexed as

5-fluorouracilChemotherapyColorectal cancerResveratrolSystemic review

Identifiers

PMID35366874
PMCPMC8976963
OpenAlexW4225713321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.